These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 28795294)

  • 1. How Long Does Antimycobacterial Antibiotic-loaded Bone Cement Have In Vitro Activity for Musculoskeletal Tuberculosis?
    Lee JH; Han CD; Cho SN; Yang IH; Lee WS; Baek SH; Shin JW; Husein KEI; Park KK
    Clin Orthop Relat Res; 2017 Nov; 475(11):2795-2804. PubMed ID: 28795294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoniazid could be used for antibiotic-loaded bone cement for musculoskeletal tuberculosis: an in vitro study.
    Han CD; Oh T; Cho SN; Yang JH; Park KK
    Clin Orthop Relat Res; 2013 Jul; 471(7):2400-6. PubMed ID: 23504536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the Effectiveness and Mechanical Strength of Kanamycin-Loaded Bone Cement in Musculoskeletal Tuberculosis Compare to Vancomycin-Loaded Bone Cement.
    Lee JH; Shin SJ; Cho SN; Baek SH; Kim DH; Park KK
    J Arthroplasty; 2020 Mar; 35(3):864-869. PubMed ID: 31708292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
    Cavanaugh JS; Jou R; Wu MH; Dalton T; Kurbatova E; Ershova J; Cegielski JP;
    J Antimicrob Chemother; 2017 Jun; 72(6):1678-1687. PubMed ID: 28333192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis.
    Solapure S; Dinesh N; Shandil R; Ramachandran V; Sharma S; Bhattacharjee D; Ganguly S; Reddy J; Ahuja V; Panduga V; Parab M; Vishwas KG; Kumar N; Balganesh M; Balasubramanian V
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2506-10. PubMed ID: 23507276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination.
    Pagliotto AD; Caleffi-Ferracioli KR; Lopes MA; Baldin VP; Leite CQ; Pavan FR; Scodro RB; Siqueira VL; Cardoso RF
    J Microbiol Immunol Infect; 2016 Dec; 49(6):980-983. PubMed ID: 26454420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibilities of nontuberculosis mycobacterial species to amoxicillin-clavulanic acid alone and in combination with antimycobacterial agents.
    Utrup LJ; Moore TD; Actor P; Poupard JA
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1454-7. PubMed ID: 7492084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae.
    Berry V; Hoover J; Singley C; Woodnutt G
    Antimicrob Agents Chemother; 2005 Mar; 49(3):908-15. PubMed ID: 15728883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Repurposed Drug Diosmin with Amoxicillin-Clavulanic acid Causes Synergistic Inhibition of Mycobacterial Growth.
    Pushkaran AC; Vinod V; Vanuopadath M; Nair SS; Nair SV; Vasudevan AK; Biswas R; Mohan CG
    Sci Rep; 2019 May; 9(1):6800. PubMed ID: 31043655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of amoxicillin/clavulanate in patients with tuberculosis.
    Chambers HF; Kocagöz T; Sipit T; Turner J; Hopewell PC
    Clin Infect Dis; 1998 Apr; 26(4):874-7. PubMed ID: 9564467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.
    Gonzalo X; Drobniewski F
    J Antimicrob Chemother; 2013 Feb; 68(2):366-9. PubMed ID: 23070734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis.
    Bergmann JS; Woods GL
    Int J Tuberc Lung Dis; 1998 Aug; 2(8):621-6. PubMed ID: 9712275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
    Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
    Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium fortuitum and Mycobacterium chelonei to augmentin.
    Casal M; Rodriguez F; Benavente M; Luna M
    Eur J Clin Microbiol; 1986 Aug; 5(4):453-4. PubMed ID: 3093225
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of sensitivity of Mycobacterium spp. to combinations of clavulanic acid & penicillins with certain antitubercular agents.
    Bhattacharya CP; Charkrabarty AN; Dastidar SG
    Indian J Med Res; 1988 Aug; 88():118-23. PubMed ID: 3198169
    [No Abstract]   [Full Text] [Related]  

  • 16. Development and validation of stability indicating HPLC methods for related substances and assay analyses of amoxicillin and potassium clavulanate mixtures.
    Bellur Atici E; Yazar Y; Ağtaş Ç; Ridvanoğlu N; Karlığa B
    J Pharm Biomed Anal; 2017 Mar; 136():1-9. PubMed ID: 28049058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis.
    Cynamon MH; Palmer GS
    Antimicrob Agents Chemother; 1983 Sep; 24(3):429-31. PubMed ID: 6416162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial.
    Gurumurthy M; Verma R; Naftalin CM; Hee KH; Lu Q; Tan KH; Issac S; Lin W; Tan A; Seng KY; Lee LS; Paton NI
    J Antimicrob Chemother; 2017 Jul; 72(7):2012-2019. PubMed ID: 28333342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of different resistance traits on the competitive growth of Haemophilus influenzae in antibiotic-free medium and selection of resistant populations by different {beta}-lactams: an in vitro pharmacodynamic approach.
    González N; Aguilar L; Alou L; Giménez MJ; Sevillano D; Torrico M; Cafini F; Coronel P; Prieto J
    J Antimicrob Chemother; 2009 Jun; 63(6):1215-22. PubMed ID: 19307171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics.
    Cohen KA; El-Hay T; Wyres KL; Weissbrod O; Munsamy V; Yanover C; Aharonov R; Shaham O; Conway TC; Goldschmidt Y; Bishai WR; Pym AS
    EBioMedicine; 2016 Jul; 9():170-179. PubMed ID: 27333036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.